Pegylated Long-Acting Growth Hormone NNC126-0083 Shows Promising Safety and Pharmacokinetics in Phase 1 Trial
Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®
Study Design
Population
Not specified in the digest, but implied to be human subjects in a Phase 1 trial.
Intervention
Pegylated long-acting growth hormone NNC126-0083; dose, route, and duration are not specified.
Outcome
The primary outcomes measured were safety and pharmacokinetics of NNC126-0083.
Abstract
A Randomised, Double Blind, Placebo-controlled, Single Dose, Dose-escalating Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pegylated Long-acting Human Growth Hormone (NNC126-0083) Compared to Norditropin…